Botulinum toxin type B for treatment of axillar hyperhidrosis

被引:65
|
作者
Dressler, D
Saberi, FA
Benecke, R
机构
[1] Univ Rostock, Dept Neurol, D-18147 Rostock, Germany
[2] Klinikum Nord, Botulinum Toxin Clin, Dept Neurol, Hamburg, Germany
关键词
botulinum toxin type B; therapy; axillar hyperhydrosis; conversion factor;
D O I
10.1007/s00415-002-0929-4
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Recently, botulinum toxin type B (BT-B) became commercially available for treatment of cervical dystonia. It is the aim of this study to explore its use for treatment of bilateral axillar hyper-hydrosis (HH). For this we directly compared the antihyperhydrotic effect of BTB (NeuroBloc(R)/MyoBloc(TM)) with that of botulinum toxin type A (BT-A) (Botox(R)). 9 patients (HD group) received BT-A 100MU unilaterally and BT-B 4000MU contralaterally. 10 patients (LD group) received BT-A 100MU and BT-B 2000MU All patients were blinded as to which preparation was used in which side. All patients except one reported excellent HH improvement in both axillae. None of the patients had residual HH on clinical examination. The duration of HH improvement until first recurrence in the HD group was 16.0 +/- 4.3 weeks in the BT-A treated axillar and 16.4 +/- 4.5 weeks in the BT-B treated axillae (Wilcoxon rank-sum test, p = 0.336). In the LD group it was 16.4 +/- 5.3 weeks in the BT-B treated axillae and 17.1 +/- 5.7 weeks in the BT-A treated axillae (Wilcoxon rank-sum test, p = 0.059). There was also no difference in the duration of HH improvement between the axillae treated with BT-B 4000MU and BT-B 2000MU (Wilcoxon rank-sum test, p = 0.712). 5 out of 9 patients in the HD group (chi-square test, p = 0.025) and 7 out of 10 patients in the LD group (chi-square test, p = 0.008) reported more application discomfort in the BT-B treated axillae. In 6 out of 9 patients in the HD group (chi-square test, p = 0.014) and in 6 out of 10 patients in the LD group (chi-square test, p = 0.014) the onset of HH improvement appeared earlier in the BT-B treated axillae. One patient in the HD group reported dryness of the mouth and eyes and accomodation difficulties. BT-B is a safe and efficient treatment for axillar HH. Doses of BT-B 2000MU per axilla seem sufficient indicating a conversion factor between BT-A and BT-B in the order of 1:20. With a conversion factor for cervical dystonia in the order of 1:40 the autonomic nervous system seems to be relatively more sensitive to BT-B than to BT-A compared with the motor system.
引用
收藏
页码:1729 / 1732
页数:4
相关论文
共 50 条
  • [21] Botulinum toxin type B for cervical dystonia
    Marques, Raquel E.
    Duarte, Goncalo S.
    Rodrigues, Filipe B.
    Castelao, Mafalda
    Ferreira, Joaquim
    Sampaio, Cristina
    Moore, A. Peter
    Costa, Joao
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (05):
  • [22] Bilateral forearm intravenous regional anesthesia with prilocaine for botulinum toxin treatment of palmar hyperhidrosis
    Enroth, Sofia Bosdotter
    Rystedt, Alma
    Covaciu, Lucian
    Hymnelius, Kristina
    Rystedt, Einar
    Nyberg, Rebecka
    Naver, Hans
    Swartling, Carl
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 63 (03) : 466 - 474
  • [23] Treatment of severe bruxism with botulinum toxin type A
    Alonso-Navarro, Hortensia
    Jimenez-Jimenez, Felix J.
    Plaza-Nieto, Jose F.
    Pilo-De la Fuente, Belen
    Navacerrada, Francisco
    Arroyo-Solera, Margarita
    Calleja, Marisol
    REVISTA DE NEUROLOGIA, 2011, 53 (02) : 73 - 76
  • [24] First clinical experience with botulinum toxin type B
    Dressler, D
    Benecke, R
    NERVENARZT, 2002, 73 (02): : 194 - 198
  • [25] Practical aspects of using botulinum toxin type B
    Barnes, MP
    EUROPEAN JOURNAL OF NEUROLOGY, 2001, 8 : 19 - 21
  • [26] Botulinum Toxin Type A in the Treatment of Raynaud's Phenomenon
    Neumeister, Michael W.
    JOURNAL OF HAND SURGERY-AMERICAN VOLUME, 2010, 35A (12): : 2085 - 2092
  • [27] Treatment of Raynaud’s phenomenon with botulinum toxin type A
    Xiaolong Zhang
    Yong Hu
    Zhiyu Nie
    Ye Song
    Yougui Pan
    Ying Liu
    Lingjing Jin
    Neurological Sciences, 2015, 36 : 1225 - 1231
  • [28] Treatment of Raynaud's phenomenon with botulinum toxin type A
    Zhang, Xiaolong
    Hu, Yong
    Nie, Zhiyu
    Song, Ye
    Pan, Yougui
    Liu, Ying
    Jin, Lingjing
    NEUROLOGICAL SCIENCES, 2015, 36 (07) : 1225 - 1231
  • [29] CT-Guided Chemical Thoracic Sympathectomy versus Botulinum Toxin Type A Injection for Palmar Hyperhidrosis
    Yang, HongJun
    Kang, Jianjie
    Zhang, Shufen
    Peng, Kairun
    Deng, Bingmei
    Cheng, Biao
    THORACIC AND CARDIOVASCULAR SURGEON, 2019, 67 (05) : 402 - 406
  • [30] Botulinum toxin type B: a new therapy for axillary hyperhidrosin
    Nelson, L
    Bachoo, P
    Holmes, J
    BRITISH JOURNAL OF PLASTIC SURGERY, 2005, 58 (02): : 228 - 232